Keywords: Merck KGaA, Serono, China, R&D, Investment
Merck KGaA to boost R&D presence in China with $223 million investment
Article | 23 November 2009
German drug major Merck KGaA is the latest in a string of multinationals to view China as a good base for acquisition and research investment, today announcing it plans to strengthen the global R&D capabilities of its Merck Serono division by establishing a global R&D center in Beijing, China. Merck is planning to invest more than 150 million euros ($222.8 million) and create more than 200 new qualified jobs over the next four years to set up the China R&D center and conduct R&D activities in China.
M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
